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Background
Shortening the course of treatment for tuberculosis would be a major improvement 
for case management and disease control. This phase 3 trial assessed the efficacy 
and safety of a 4-month gatifloxacin-containing regimen for treating rifampin-
sensitive pulmonary tuberculosis.
Methods
We conducted a noninferiority, randomized, open-label, controlled trial involving pa-
tients 18 to 65 years of age with smear-positive, rifampin-sensitive, newly diagnosed 
pulmonary tuberculosis in five sub-Saharan African countries. A standard 6-month 
regimen that included ethambutol during the 2-month intensive phase was com-
pared with a 4-month regimen in which gatifloxacin (400 mg per day) was substi-
tuted for ethambutol during the intensive phase and was continued, along with ri-
fampin and isoniazid, during the continuation phase. The primary efficacy end 
point was an unfavorable outcome (treatment failure, recurrence, or death or study 
dropout during treatment) measured 24 months after the end of treatment, with a 
noninferiority margin of 6 percentage points, adjusted for country.
Results
A total of 1836 patients were assigned to the 4-month regimen (experimental group) 
or the standard regimen (control group). Baseline characteristics were well balanced 
between the groups. At 24 months after the end of treatment, the adjusted differ-
ence in the risk of an unfavorable outcome (experimental group [21.0%] minus 
control group [17.2%]) in the modified intention-to-treat population (1356 patients) 
was 3.5 percentage points (95% confidence interval, −0.7 to 7.7). There was hetero-
geneity across countries (P = 0.02 for interaction, with differences in the rate of an 
unfavorable outcome ranging from −5.4 percentage points in Guinea to 12.3 per-
centage points in Senegal) and in baseline cavitary status (P = 0.04 for interaction) 
and body-mass index (P = 0.10 for interaction). The standard regimen, as compared 
with the 4-month regimen, was associated with a higher dropout rate during treat-
ment (5.0% vs. 2.7%) and more treatment failures (2.4% vs. 1.7%) but fewer recur-
rences (7.1% vs. 14.6%). There was no evidence of increased risks of prolongation of 
the QT interval or dysglycemia with the 4-month regimen.
Conclusions
Noninferiority of the 4-month regimen to the standard regimen with respect to the 
primary efficacy end point was not shown. (Funded by the Special Program for 
Research and Training in Tropical Diseases and others; ClinicalTrials.gov number, 
NCT00216385.)
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Shortened antituberculosis treat-ment regimens are expected to improve pa-tient adherence to treatment, thus favoring 
better case management and disease control and 
minimizing the risk of drug resistance.1-3 The 
first indication that fluoroquinolones had the 
potential to shorten tuberculosis treatment was 
from an observational study in India4 in which 
ethambutol was replaced with ofloxacin. The 
fourth-generation fluoroquinolones gatifloxacin 
and moxifloxacin have shown mycobactericidal 
activity that is better than that of ofloxacin in 
vitro5 and in vivo,6-9 and these agents have the 
potential to shorten treatment. Gatifloxacin was 
chosen for this study on the basis of its bacteri-
cidal-activity profile, cost, and generic status. 
We conducted a phase 3 trial that evaluated the 
efficacy and safety of a 4-month gatifloxacin-
containing regimen, as compared with a standard 
6-month regimen, for the treatment of rifampin-
sensitive pulmonary tuberculosis.
Me thods
Study Population
Patients were recruited from cities in five sub-
Saharan African countries: Cotonou in Benin, 
Conakry in Guinea, Nairobi in Kenya, Dakar in 
Senegal, and Durban in South Africa. Eligible 
patients were 18 to 65 years of age, with newly 
diagnosed, microbiologically confirmed pulmo-
nary tuberculosis, as determined by the presence 
of acid-fast bacilli in two consecutive sputum 
smears; all patients provided written informed 
consent. The main exclusion criteria were a his-
tory of tuberculosis treatment during the previous 
3 years, a history of insulin-dependent or non–
insulin-dependent diabetes mellitus requiring 
treatment (because of potential glycemic imbal-
ance in persons with tuberculosis), concomitant 
infection requiring additional anti-infective treat-
ment, and human immunodeficiency virus (HIV) 
infection with World Health Organization (WHO) 
stage 3 disease (unless loss of >10% of body 
weight was the only criterion met) or stage 4 dis-
ease. For a full list of exclusion criteria, see the 
study protocol, available with the full text of this 
article at NEJM.org.
Study Design
This was a randomized, open-label, noninferior-
ity, multicenter, controlled trial with a nested 
pharmacokinetic and pharmacokinetic–pharma-
codynamic study.10 Patients were randomly as-
signed, in a 1:1 ratio with stratification accord-
ing to country, to either a gatifloxacin-containing 
regimen (experimental group) or the 6-month 
standard treatment (control group).11
The control regimen consisted of isoniazid, 
rifampin, pyrazinamide, and ethambutol during 
the intensive phase of treatment (2 months), fol-
lowed by isoniazid and rifampin during the con-
tinuation phase (4 months). The dosage of iso-
niazid, rifampin, pyrazinamide, and ethambutol 
followed WHO guidelines.11 In the experimental 
regimen, gatifloxacin (400 mg once daily irre-
spective of body weight [standard dose for treat-
ment of infections]) was substituted for etham-
butol during the intensive phase (2 months) and 
was maintained along with isoniazid and rifam-
pin during the continuation phase (2 months).10 
(For details on the treatment regimens, see Sec-
tion S2 in the Supplementary Appendix, available 
at NEJM.org.) Fixed-dose combination tablets of 
isoniazid–rifampin, isoniazid–rifampin–pyrazina-
mide, or isoniazid–rifampin–pyrazinamide–eth-
ambutol were manufactured and provided by 
Lupin Pharmaceuticals (Mumbai, India) in com-
pliance with international manufacturing prac-
tice standards. Lupin Pharmaceuticals had no 
role in the conduct of the trial, the analysis of 
the data, or the preparation of the manuscript. 
All trial drugs were administered orally under 
supervision 6 days a week during the intensive 
phase and were provided every 2 weeks thereaf-
ter. Adherence was assessed by a count of the 
tablets that remained in weekly treatment boxes.
Clinical and laboratory evaluations were per-
formed at baseline (before treatment), every 
month during the treatment phase, and every 2 or 
3 months after the end of treatment for a total 
follow-up period of 24 months. Two sputum 
samples were obtained for direct smear exami-
nation, culture (solid medium), and drug-sensitiv-
ity tests at baseline and at all subsequent visits 
(Section S3 in the Supplementary Appendix). 
Initially, blood glucose was measured at 4 weeks 
and 8 weeks after the first drug intake and at the 
end of treatment; subsequently, on the advice of 
the data and safety monitoring board, blood glu-
cose was measured more frequently (at 4 hours 
and 1, 2, and 12 weeks after the first drug in-
take). We obtained 12-lead electrocardiograms at 
baseline and between 1 and 5 hours after drug 
intake at 4 weeks, 8 weeks, and the end of treat-
ment. (A timetable of all evaluations is provided 
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in the protocol.) The trial was conducted in com-
pliance with Good Clinical Practice and Good 
Clinical Laboratory Practice guidelines. Quality-
control and quality-assurance procedures were 
in place, including external quality control of 
microbiologic results by the Institute of Tropical 
Medicine, in Antwerp, Belgium; regular on-site 
monitoring visits with source-data verification 
for 100% of the data collected; and clinical au-
dits of the trial sites (Section S4 in the Supple-
mentary Appendix).
Study Oversight
The data and safety monitoring board reviewed 
trial data twice a year, with prespecified interim 
reviews of efficacy and safety. The protocol was 
approved by the national regulatory authorities 
in the participating countries and by the institu-
tional review board or independent ethics com-
mittee at each participating site. The authors 
vouch for the completeness and accuracy of the 
data presented and for the fidelity of the study to 
the protocol.
End Points
The primary efficacy end point was the percent-
age of participants with an unfavorable outcome 
by 24 months after the end of treatment. This 
composite outcome included treatment failure 
(at either 4 months or 6 months after randomiza-
tion, depending on the treatment group), recur-
rence (relapse or reinfection), and death or with-
drawal from the study during the treatment phase. 
Treatment failure and recurrence were defined as 
positive results of two consecutive sputum cul-
tures at least 1 day apart. When the outcome 
could not be determined, the case was submitted 
to an independent end-points committee, whose 
members were unaware of the study-group as-
signments. Participants with negative cultures at 
the end of follow-up were considered to have had 
a favorable outcome.
Secondary efficacy end points and safety end 
points included smear and culture conversion at 
8 weeks, an unfavorable outcome at the end of 
treatment (treatment failure, death, or dropout), 
recurrence, an unfavorable outcome 18 months 
after randomization, the time to an unfavorable 
outcome by 24 months after the end of treat-
ment, serious adverse events, hyperglycemia dur-
ing the treatment phase, and prolongation of the 
QT interval (corrected QT [QTc] interval, calcu-
lated with Fridericia’s formula or Bazett’s for-
mula, of >480 msec).12,13
Statistical Analysis
In the initial sample-size calculation, recurrence 
was used as the primary outcome (Section S1 in 
the Supplementary Appendix). The calculation 
was subsequently revised to allow for the above-
mentioned composite end point as the primary 
outcome.10 The sample size was based on a one-
sided formula14 for equivalence, because the risk 
of an unfavorable outcome in the experimental 
group was not expected to be less than that in 
the control group. Assuming a 20% risk of an 
unfavorable outcome at 24 months after the end 
of treatment, we calculated that with 697 patients 
in each group, the study would have 80% power 
to show noninferiority of the experimental regi-
men versus the control regimen with a margin of 
6 percentage points at a one-sided level of signifi-
cance of 0.025. To ensure that the study would be 
powered for both the intention-to-treat and per-
protocol analyses and assuming that we would 
not be able to assess the primary outcome for 
15% of the patients, we calculated that 820 pa-
tients had to be enrolled in each group (1640 in 
total).10
For all binary efficacy end points, we calcu-
lated the absolute difference in the proportion of 
patients with an unfavorable outcome, with ad-
justment for country, in the modified intention-
to-treat and per-protocol populations. The mod-
ified intention-to-treat population consisted of 
all patients who underwent randomization and 
received the study medication at least once, ex-
cluding patients with suspected or confirmed 
rifampin-resistant tuberculosis. All patients in-
cluded in the modified intention-to-treat analy-
sis who missed no more than two consecutive 
doses during the intensive phase of treatment or 
no more than six consecutive doses during the 
continuation phase and who took at least 80% of 
all doses over a period of 4 months (experimental 
group) or 6 months (control group) were included 
in the per-protocol analysis. The time to an un-
favorable outcome and the time to recurrence 
were analyzed with the use of Cox proportional-
hazards regression (Section S5 in the Supple-
mentary Appendix).
Prespecified subgroup analyses of the pri-
mary end point were performed according to 
country, HIV status, status with respect to iso-
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niazid resistance, and extent of pulmonary dis-
ease (on the basis of the zone score, which 
ranges from 0 to 6, with 0 indicating that no 
lung regions are affected and 6 indicating that 
all lung regions are affected). Additional post hoc 
subgroup analyses were performed according to 
a body-mass index (BMI, the weight in kilograms 
divided by the square of the height in meters) of 
less than 16 (severe undernourishment) versus 
16 or more15 and status with respect to cavitary 
disease.16
Safety analyses were conducted in the inten-
tion-to-treat population. Serious adverse events, 
prolongation of the QTc interval, and dysglyce-
mia are reported in this article.
R esult s
Baseline Characteristics of the Patients
From June 2005 through October 2009, a total of 
1836 patients were enrolled: 316 in Benin, 452 in 
Guinea, 200 in Kenya, 358 in Senegal, and 510 in 
South Africa (Fig. 1). The number of patients as-
signed to each group and the exclusions at each 
stage were well balanced, except in the per-pro-
tocol population, owing to a higher dropout rate 
during treatment in the control group than in the 
experimental group. All 138 patients enrolled in 
one center were excluded owing to evidence of 
fraudulent conduct.
The baseline characteristics of the patients 
were similar in the two treatment groups (Table 
1, and Tables S1 and S2 in the Supplementary 
Appendix). Approximately 18% of the partici-
pants were HIV-positive. Half the participants 
presented with advanced pulmonary tuberculo-
sis: 51% had a smear reading of 3+, 51% had 
cavitary pulmonary tuberculosis, and 44% had a 
zone score of 4 to 6 on chest radiography.
Efficacy
Primary Efficacy End Point
A total of 1356 patients (694 in the experimental 
group and 662 in the control group) were includ-
ed in the modified intention-to-treat analysis of 
the primary efficacy end point (Table 2). Overall, 
the country-adjusted difference (experimental 
group minus control group) in the rate of unfa-
vorable outcome was 3.5 percentage points, with 
an upper boundary of the one-sided 97.5% confi-
dence interval (CI) of 7.7. In the per-protocol 
analysis (Table 2), the difference between groups 
was slightly larger in favor of the control group 
(adjusted difference, 5.5 percentage points; upper 
boundary of the one-sided 97.5% CI, 9.4). Results 
were consistent for the time to an unfavorable 
outcome, with a country-adjusted hazard ratio 
(experimental group vs. control group) of 1.31 
(95% CI, 1.02 to 1.67) in the modified intention-
to-treat population.
The reasons for unfavorable outcomes dif-
fered in the two treatment groups (Table 3, and 
Tables S3 and S4 in the Supplementary Appen-
dix). More patients in the control group than in 
the experimental group dropped out during 
treatment (5.0% vs. 2.7%) and had treatment 
failure (2.4% vs. 1.7%), whereas more patients in 
the experimental group than in the control 
group had a recurrence of tuberculosis (14.6% 
vs. 7.1%).
The prespecified subgroup analysis according 
to country in the modified intention-to-treat 
population showed heterogeneity of treatment 
effect (P = 0.02 for interaction between country 
and treatment group) (Fig. 2, and Table S5 in the 
Supplementary Appendix). Between-group dif-
ferences in the rate of an unfavorable outcome 
ranged from –5.4 percentage points (Guinea) to 
12.3 percentage points (Senegal).
Baseline HIV status, prevalence of cavitary 
pulmonary disease, and BMI varied among 
countries (Table S2 in the Supplementary Ap-
pendix). A prespecified subgroup analysis ac-
cording to HIV status in the modified intention-
to-treat population showed fewer unfavorable 
outcomes in the experimental group than in the 
control group among HIV-positive patients (dif-
ference in the rate of an unfavorable outcome, 
−4.0 percentage points; 95% CI, −15.7 to 7.6; 
P = 0.12 for interaction) (Fig. 2, and Table S5 in 
the Supplementary Appendix). The variability of 
treatment effect according to country was fur-
ther explored through post hoc subgroup analy-
ses according to cavitary disease on chest radi-
ography and BMI at baseline. The proportion of 
patients with an unfavorable outcome was simi-
lar in the two groups among those with non-
cavitary disease (difference, −1.3 percentage 
points; 95% CI, −7.3 to 4.6; P = 0.04 for interac-
tion) and among those with a BMI of less than 
16 (difference, −0.4 percentage points; 95% CI, 
−6.7 to 5.9; P = 0.10 for interaction), but there 
were better outcomes in the control group than 
in the experimental group among patients with 
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1836 Underwent randomization and received
medication on at least one occasion
5845 Patients were screened
4009 Were excluded
917 Were assigned to experimental group 919 Were assigned to control group
69  Withdrew from study
64 Were at a site with major
protocol violations
4 Had negative TB smear
1 Had QTc interval 
>480 msec at baseline
75 Withdrew from study
74 Were at a site with major
protocol violations
1 Had negative TB smear
848 Were included in intention-to-treat
analysis
844 Were included in intention-to-treat
analysis
57 Withdrew from study
11 Had isolates that were
resistant to rifampin on
MGIT
44 Had invalid MGIT test
result
2 Had isolates that were
resistant to rifampin and
isoniazid on L–J culture
50 Withdrew from study
11 Had isolates that were
resistant to rifampin on
MGIT
34 Had invalid MGIT test
result
5 Had isolates that were
resistant to rifampin and
isoniazid on L–J culture
791 Were included in modified intention-
to-treat analysis
694 Were included in primary outcome
analysis
794 Were included in modified intention-
to-treat analysis
662 Were included in primary outcome
analysis
41 Were excluded owing
to inadequate adherence
to treatment
63 Were excluded owing
to inadequate adherence
to treatment
651 Were included in the per-protocol
primary outcome analysis
601 Were included in the per-protocol
primary outcome analysis
Figure 1. Enrollment and Outcomes.
Inadequate adherence to treatment was defined as missing more than two consecutive doses during the intensive 
phase, more than six consecutive doses during the continuation phase, or more than 20% of all doses over a period 
of 4 months (experimental group) or 6 months (control group). Of 41 patients in the experimental group with inade-
quate adherence to treatment, 14 were in Benin, 18 were in Guinea, 1 was in Kenya, 5 were in Senegal, and 3 were in 
South Africa. Of 63 patients the control group with inadequate adherence to treatment, 21 were in Benin, 30 were 
in Guinea, 4 were in Kenya, 6 were in Senegal, and 2 were in South Africa. A total of 2 patients (1 each in Benin and 
South Africa) were assigned to the experimental group but received the control regimen. In the per-protocol analy-
sis, these patients were analyzed on the basis of the regimen received, so the number of patients included in the 
analysis was 651 (653 − 2) in the experimental group and 601 (599 + 2) in the control group. L–J denotes Lowenstein–
Jensen solid medium, MGIT mycobacterial growth indicator tube system, QTc corrected QT, and TB tuberculosis.
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cavitary disease and among those with a BMI of 
16 or more. There was no evidence of a signifi-
cant interaction of treatment group with isoniazid 
resistance or with zone score on chest radiogra-
phy at baseline (P = 0.47 for both comparisons).
Secondary Efficacy End Points
Outcomes at 2 months after randomization and 
at the end of treatment were similar in the ex-
perimental and control groups. At 18 months 
after randomization, the experimental regimen 
was inferior to the control regimen in both the 
modified intention-to-treat and per-protocol 
populations (Table 2).
The country-adjusted hazard ratio (experi-
mental group vs. control group) for the time to 
recurrence among those with a favorable out-
come at the end of treatment was 2.25 (95% CI, 
1.59 to 3.18) (Table 2). There was strong evi-
dence for nonproportional hazards with regard 
to treatment effect (P = 0.004): the country-ad-
justed hazard ratio up to 20 weeks after the end 
of treatment was 4.42 (95% CI, 2.53 to 7.76), as 
compared with a hazard ratio of 1.22 (95% CI, 
0.74 to 2.01) at more than 20 weeks after the end 
of treatment (Fig. S1 in the Supplementary Ap-
pendix). Of 140 patients with culture-positive 
recurrence, 77 (55%) had strains genotyped by 
means of a 15-locus mycobacterial interspersed 
repetitive unit–variable-number tandem-repeat 
analysis. Of these 77 patients, 15 of 20 patients 
in the experimental group (75%) and 46 of 57 
patients in the control group (81%) had a relapse 
(P = 0.75).
Safety
Serious Adverse Events
Overall, 43 serious adverse events were recorded 
in 43 patients; 5 of these events were judged to be 
related to the study medication. There were no 
significant differences between the groups with 
regard to the percentage of patients with at least 
one serious adverse event and the percentage of 
serious adverse events that were judged to be re-
lated to the study medication (P = 0.65 for both 
comparisons) (Tables S7, S8, and S9 in the Sup-
plementary Appendix).
QTc Interval
There was no increased risk of an abnormal peak 
value of the QTc interval in the experimental 
group as compared with the control group. The 
risk difference (experimental group minus con-
trol group) was −0.4 percentage points with the 
QTc interval calculated with Bazett’s formula12 
and −0.9 percentage points with the interval cal-
culated with Fridericia’s formula13 (Table S10 in 
the Supplementary Appendix).
Blood Glucose
The vast majority of the patients had normal 
blood glucose levels throughout the course of 
treatment (94.6% in the experimental group and 
Table 1. Baseline Characteristics of Patients in the Intention-to-Treat 
Population.*
Characteristic
Experimental Group
(N = 848)
Control Group
(N = 844)
Country — no. (%)
Benin 158 (18.6) 158 (18.7)
Guinea 221 (26.1) 225 (26.7)
Kenya 100 (11.8) 100 (11.8)
Senegal 178 (21.0) 180 (21.3)
South Africa 191 (22.5) 181 (21.4)
Age — yr 30.9±9.1 30.6±9.0
Female sex — no. (%) 229 (27.0) 233 (27.6)
Body-mass index† 17.4±4.9 17.5±5.0
Weight — kg 53.8±7.7 54.2±8.0
HIV positivity — no./total no. (%) 147/843 (17.4) 157/838 (18.7)
Smear findings — no./total no. (%)‡
1+ 129/847 (15.2) 141/842 (16.7)
2+ 273/847 (32.2) 287/842 (34.1)
3+ 445/847 (52.5) 414/842 (49.2)
Positive culture — no./total no. (%) 824/838 (98.3) 821/833 (98.6)
Isoniazid resistance — no./total no. (%) 41/617 (6.6) 53/622 (8.5)
Cavitation — no./total no. (%) 440/845 (52.1) 417/837 (49.8)
Bilateral lung disease — no./total no. (%) 508/838 (60.6) 523/832 (62.9)
Zone score of 4 to 6 — no./total no. (%)§ 366/841 (43.5) 363/833 (43.6)
Corrected QT interval — msec¶ 415.1±22.7 414.7±25.8
* Plus–minus values are means ±SD. Patients who could not be assessed for the 
efficacy outcomes were excluded from the analysis. HIV denotes human immu-
nodeficiency virus.
† The body-mass index is the weight in kilograms divided by the square of the 
height in meters.
‡ Smear findings were scored 1+ to 3+, with higher numbers indicating more 
severe disease.
§ The zone score ranges from 0 to 6, with 0 indicating that no lung regions are 
affected and 6 indicating that all lung regions are affected.
¶ The QT interval was corrected for heart rate according to Bazett’s formula.
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94.2% in the control group). Four patients, two 
in each study group, had grade 4 hyperglycemia 
(blood glucose >27.5 mmol per liter). No signifi-
cant between-group difference was detected in 
the risk of hyperglycemia (Table S11 in the Sup-
plementary Appendix).
Table 2. Primary and Secondary Efficacy Analyses in the Modified Intention-to-Treat Population and Per-Protocol 
Population.*
Variable Experimental Group Control Group
Adjusted Difference, 
Experimental Group− 
Control Group†
percentage points  
(95% CI)
Modified intention-to-treat analysis
Primary outcome: unfavorable outcome 24 mo after 
the end of treatment — no./total no. (%)
146/694 (21.0) 114/662 (17.2) 3.5 (−0.7 to 7.7)
Secondary outcomes
Smear-positive status at 2 mo — no./total no. (%) 118/762 (15.5) 112/759 (14.8) 0.0 (−3.0 to 2.9)
No culture conversion at 2 mo — no./total no. (%) 104/741 (14.0) 121/735 (16.5) −2.0 (−4.9 to 1.0)
Unfavorable outcome at end of treatment — no./
total no. (%)
45/781 (5.8) 67/785 (8.5) −2.4 (−4.9 to 0.0)
Unfavorable outcome 18 mo after randomization 
— no./total no. (%)
139/731 (19.0) 98/744 (13.2) 5.8 (2.0 to 9.6)
No unfavorable outcome by 24 mo after the end of 
treatment — cumulative %‡
80.7 85.5 1.31 (1.02 to 1.67)§
No recurrence by 24 mo after the end of treatment 
— cumulative %¶
85.6 93.5 2.25 (1.59 to 3.18)§
Per-protocol analysis
Primary outcome: unfavorable outcome 24 mo after 
the end of treatment — no./total no. (%)
115/651 (17.7) 68/601 (11.3) 5.5 (1.6 to 9.4)
Secondary outcomes
Smear-positive status at 2 mo — no./total no. (%) 118/752 (15.7) 111/750 (14.8) 0.0 (−2.9 to 3.0)
No culture conversion at 2 mo — no./total no. (%) 103/732 (14.1) 121/726 (16.7) −1.9 (−4.9 to 1.1)
Unfavorable outcome at end of treatment — no./
total no. (%)
17/736 (2.3) 24/716 (3.4) −1.0 (−2.7 to 0.7)‖
Unfavorable outcome 18 mo after randomization 
— no./total no. (%)
108/687 (15.7) 753/676 (7.8) 7.3 (3.9 to 10.7)
No unfavorable outcome by 24 mo after the end of 
treatment — cumulative %‡
83.7 90.6 1.73 (1.28 to 2.33)§
No recurrence by 24 mo after the end of treatment 
— cumulative %¶
85.7 93.7 2.32 (1.63 to 3.32)§
* P values for interaction of treatment with country in the modified intention-to-treat population were as follows: end of 
treatment, 0.10; 18 months after randomization, 0.04; 24 months after the end of treatment, 0.02; time to an unfavor-
able outcome, 0.04; and time to recurrence, 0.34. P values for country interaction in the per-protocol population were as 
follows: end of treatment, not assessed; 18 months after randomization, 0.05; 24 months after the end of treatment, 0.04; 
time to an unfavorable outcome, 0.12; and time to recurrence, 0.65. CI denotes confidence interval.
† Differences were adjusted according to country unless otherwise indicated.
‡ The number of patients included in the analysis was 782 in the experimental group and 785 in the control group in the modified 
intention-to-treat population and 736 in the experimental group and 716 in the control group in the per-protocol population.
§ Shown is the hazard ratio, with 95% CI, for the experimental regimen versus the standard regimen.
¶ The number of patients included in the analysis was 727 in the experimental group and 710 in the control group in the modified 
intention-to-treat population and 709 in the experimental group and 684 in the control group in the per-protocol population.
‖ The difference was not adjusted according to country (model failed to converge).
The New England Journal of Medicine 
Downloaded from nejm.org on November 18, 2014. For personal use only. No other uses without permission. 
 Copyright © 2014 Massachusetts Medical Society. All rights reserved. 
A 4-Month Regimen for Treating Tuberculosis
n engl j med 371;17 nejm.org october 23, 2014 1595
Discussion
This trial assessed the effect of shortening the 
treatment duration for rifampin-sensitive tuber-
culosis by using a fluoroquinolone-based regi-
men. Despite a small absolute difference between 
regimens (3.5 percentage points) in the propor-
tion of patients with an unfavorable outcome, the 
study failed to show that 4-month treatment with 
gatifloxacin substituted for ethambutol was non-
inferior to the 6-month standard regimen when 
a noninferiority margin of 6 percentage points 
was used. The results were consistent in the 
modified intention-to-treat and per-protocol analy-
ses. The main reason for a failure to show non-
inferiority was the higher recurrence rate ob-
served with the 4-month regimen, despite rapid 
culture conversion during treatment.
Treatment effects differed widely across coun-
tries and subgroups of patients. The risk of an 
unfavorable outcome with the 4-month regimen 
was almost twice as high in South Africa as in 
Table 3. Percentages of Favorable and Unfavorable Outcomes in the Primary Efficacy Analysis and of Outcomes That 
Could Not Be Assessed in the Modified Intention-to-Treat Population.
Variable Experimental Group Control Group
no. (%)
Favorable outcome* 548 (79.0) 548 (82.8)
Unfavorable outcome* 146 (21.0) 114 (17.2)
By end of treatment 45 (6.5) 67 (10.1)
Study dropout 19 (2.7) 33 (5.0)†
Withdrawal of consent 8 (1.2) 8 (1.2)
Adverse event other than death 1 (0.1) 1 (0.2)
Death 5 (0.7) 9 (1.4)‡
Treatment failure 12 (1.7) 16 (2.4)
After end of treatment: recurrence of tuberculosis 101 (14.6) 47 (7.1)
Two positive cultures 86 (12.4) 33 (5.0)
One positive culture 12 (1.7) 9 (1.4)
Culture-negative or unknown status§ 3 (0.4) 5 (0.8)
Outcome could not be assessed¶ 97 (12.3) 132 (16.6)
Protocol-defined withdrawal‖ 8 (1.0) 8 (1.0)
Loss to follow-up after end of treatment** 68 (8.6) 104 (13.1)
Death after end of treatment 19 (2.4) 18 (2.3)
Withdrawal of consent after end of treatment 1 (0.1) 1 (0.1)
Other reason 1 (0.1) 1 (0.1)
* The denominator used to calculate the percentages for favorable outcome and unfavorable outcome was the total 
number of patients for whom the outcome could be assessed: 694 patients in the experimental group and 662 pa-
tients in the control group.
† Of the 33 patients in the control group who dropped out during treatment, 26 (79%) dropped out during the first  
4 months of treatment and 7 (21%) dropped out during months 5 and 6.
‡ Of the 9 patients in the control group who died during treatment, 7 died during the first 4 months of treatment and  
2 died during months 5 and 6.
§ In these patients, recurrence was diagnosed on the basis of positive smears or symptoms of tuberculosis.
¶ The denominator used to calculate the percentages for Outcome could not be assessed was the number of patients 
eligible for the modified intention-to-treat population: 791 patients in the experimental group and 794 patients in the 
control group.
‖ A total of 16 patients were withdrawn from the study during treatment because they started antiretroviral therapy  
(6 patients in the experimental group and 3 patients in the control group) or became pregnant (2 patients in the ex-
perimental group and 5 patients in the control group).
** The cumulative percentage of patients retained in the experimental and control groups, respectively, was 93.5% and 
93.4% by 52 weeks, 91.0% and 89.6% by 78 weeks, and 87.5% and 82.7% by 94 weeks.
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Guinea (25.6% vs. 13.1%), with treatment effects 
(experimental group minus control group) of 
9.9 percentage points and −5.4 percentage points, 
respectively. The use of a composite outcome 
and differences in patient characteristics at base-
line might have contributed to the heterogeneity. 
The medications (which were produced according 
to Good Manufacturing Practice standards by the 
same manufacturer and adequately stored on 
site), the mycobacteriology laboratories (with pro-
cedures standardized across sites and quality 
control in place), and the open-label design of 
the study (with blinded outcome assessment by 
laboratory technicians and members of the end-
point committee)10 are unlikely contributors.
This study used a composite end point that 
included events occurring during treatment (treat-
ment failure, death, or dropout) and follow-up 
(recurrence). The contribution of these individual 
components to the overall end point varied 
among countries. Historically, a single outcome 
(cure without recurrence) was the primary efficacy 
end point17; now, however, a composite outcome 
is favored by regulators16 and is programmati-
cally more relevant as a measure of true treat-
ment effectiveness — although it is inherently 
more complex to interpret. Although more pa-
tients dropped out or died during treatment in 
the control group than in the experimental group 
(42 vs. 24), nearly 80% of the events in the con-
trol group occurred during the first 4 months of 
treatment, suggesting that the difference did not 
result from a longer risk period of treatment.
The baseline characteristics of the patients 
were similar in the two treatment groups but dif-
fered across countries: the proportion of severely 
undernourished patients was 50% in Guinea 
and Benin and 40% in the other countries, the 
prevalence of HIV positivity ranged from 1% in 
Senegal to 49% in South Africa, and the rate of 
cavitary disease was 20% in Benin, Guinea, and 
Kenya and 90% in Senegal and South Africa 
(Table S2 in the Supplementary Appendix). Sub-
group analyses therefore can help identify sourc-
es of heterogeneity; in patients who had non-
cavitary disease or were HIV-positive or severely 
undernourished, treatment effects were similar 
in the two groups, whereas in patients with 
cavitation or who were HIV-negative or had a 
BMI of more than 16, the 4-month regimen was 
inferior to standard treatment.
An inability to show noninferiority may be 
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Figure 2. Unfavorable Outcomes in the Modified Intention-to-Treat Population, Overall and According to Subgroups.
Differences were adjusted according to country (except in each country). The body-mass index (BMI) is the weight in kilograms divided 
by the square of the height in meters.
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related to insufficient drug exposure (daily and 
total dose), because the dosage of gatif loxacin 
was not adjusted on the basis of body weight, 
and treatment was administered 6 days a week. 
Hence, total exposure to a 4-month gatifloxacin 
regimen might have been insufficient for sus-
tained sterilization of the respiratory tract, espe-
cially in patients with cavitation or a higher (vs. 
lower) BMI, as suggested by some evidence of 
interaction between treatment and these factors 
with respect to the primary outcome. Further-
more, a population pharmacokinetic model based 
on the blood levels of a subgroup of these pa-
tients predicted that only 62% of the study popu-
lation would have a target ratio of area under the 
curve to minimal inhibitory concentration of 
more than 125 at steady state.18 The results of 
the nested pharmacokinetic–pharmacodynamic 
analyses may provide additional insights.
In this study, a 4-month gatifloxacin-contain-
ing regimen did not carry an increased risk of 
dysglycemia, an adverse event that has been re-
ported in older adults19 but has not been con-
firmed in other studies.20,21 In addition, there was 
no evidence of prolongation of the QT interval.
The expectations raised by the phase 2 study 
were not borne out in this phase 3 trial. The 
direction of the difference between fluoroquino-
lone-containing treatment and standard treat-
ment in achieving culture conversion at 8 weeks 
consistently favored fluoroquinolone regimens 
in all the phase 2 studies published so far,6,7,9 
although the difference reached statistical signifi-
cance in only one study.8 The 8-week outcome 
results of this phase 3 study are consistent with 
the phase 2 data but were not maintained during 
follow-up and could not reliably predict steriliz-
ing activity and recurrence. Similar disappointing 
results were found by Jindani et al.22 in a phase 
3 trial of a 4-month moxifloxacin-based regimen. 
More robust phase 2 surrogate markers of treat-
ment efficacy are needed to select suitable regi-
mens for shortening tuberculosis treatment that 
can be further assessed in phase 3 studies. It is 
possible that a 4-month treatment regimen may 
benefit a subgroup of patients with tuberculosis, 
such as those with noncavitary disease, as pro-
posed by others23 and suggested by our results.
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